The risks of legalizing cannabis drugs
Authors:
L. Csémy; K. Nešpor
Authors‘ workplace:
Ředitelka: MUDr. Zuzana Barboríková, MBA
; Psychiatrická nemocnice Bohnice, Praha
Published in:
Prakt. Lék. 2023; 103(1): 32-34
Category:
Of different specialties
Overview
The factual legalization of cannabis drugs would lead to higher consumption and a decrease in the prices of cannabis drugs on the black market. This would bring a host of complications including foetal harm, mental disorders, traffic accidents and economic losses.
Keywords:
Marijuana – cannabis – risks – legalization
Sources
1. Bouquet E, Pain S, Eiden C, et al. Adverse events of recreational cannabis use reported to the French addictovigilance network (2012–2017). Br J Clin Pharmacol 2021; 87(10): 3925–3937.
2. Crocker CE, Carter AJE, Emsley JG, et al. When cannabis use goes wrong: mental health side effects of cannabis use that present to emergency services. Front Psychiatry 2021; 12: 640222.
3. Dahlgren MK, Sagar KA, Smith RT, et al. Recreational cannabis use impairs driving performance in the absence of acute intoxication. Drug Alcohol Depend 2020; 208: 107771.
4. Dellazizzo L, Potvin S, Dou BY, et al. Association between the use of cannabis and physical violence in youths: a meta-analytical investigation. Am J Psychiatry 2020; 177(7): 619–626.
5. Diep C, Bhat V, Wijeysundera DN, et al. The association between recent cannabis use and suicidal ideation in adults: a population- based analysis of the NHANES from 2005 to 2018. Can J Psychiatry 2022; 67(4): 259–267.
6. Fischer B, Lee A, O‘Keefe-Markman C, Hall W. Initial indicators of the public health impacts of non-medical cannabis legalization in Canada. EClinicalMedicine 2020; 20: 100294.
7. Gesterling L, Bradford H. Cannabis use in pregnancy: a state of the science review. J Midwifery Womens Health 2022; 67(3): 305–313.
8. Goyal H, Awad HH, Ghali JK. Role of cannabis in cardiovascular disorders. J Thorac Dis 2017; 7: 2079–2092.
9. Grundy Q, Imahori D, Mahajan S, et al. Cannabis companies and the sponsorship of scientific research: A cross-sectional Canadian case study. PLoS One 2023; 18(1): e0280110.
10. Gunadi C, Zhu B, Shi Y. Recreational cannabis legalization and transitions in cannabis use: findings from a nationally representative longitudinal cohort in the United States. Addiction 2022; 117(10): 2651–2659.
11. Hengartner MP, Angst J, Ajdacic-Gross V, Rössler W. Cannabis use during adolescence and the occurrence of depression, suižencidality and anxiety disorder across adulthood: Findings from a longitudinal cohort study over 30 years. J Affect Disord 2020; 272: 98–103.
12. Chomynová P, Grohmannová K, Dvořáková Z. Zpráva o nelegálních drogách v České republice 2022. Úřad vlády České republiky 2022; 246.
13. Imtiaz S, Nigatu YT, Ali F, et al. Cannabis legalization and cannabis use, daily cannabis use and cannabis-related problems among adults in Ontario, Canada (2001–2019). Drug Alcohol Depend 2023; 244: 109765.
14. Kim C, Chum A, Nielsen A, et al. Associations between recreational cannabis legalization and cannabis-related emergency department visits by age, gender, and geographic status in Ontario, Canada: An interrupted time series study. PLoS One 2022; 17(10): e0268718.
15. Kimbrel NA, Meyer EC, DeBeer BB, et al. The impact of cannabis use disorder on suicidal and nonsuicidal self-injury in iraq/afghanistan- era veterans with and without mental health disorders. Suicide Life Threat Behav 2018; 48(2): 140–148.
16. Lalli M, Brouillette K, Kapczinski F, de Azevedo Cardoso T. Substance use as a risk factor for bipolar disorder: A systematic review. J Psychiatr Res 2021; 144: 285–295.
17. Lin AL, Nah G, Tang JJ, et al. Cannabis, cocaine, methamphetamine, and opiates increase the risk of incident atrial fibrillation. Eur Heart J 2022; 43(47): 4933–4942.
18. Luke S, Hobbs AJ, Smith M, et al. National Maternal Cannabis Working Group. Cannabis use in pregnancy and maternal and infant outcomes: A Canadian cross-jurisdictional population-based cohort study. PLoS One 2022; 17(11): e0276824.
19. Matheson J, Le Foll B. Cannabis legalization and acute harm from high potency cannabis products: a narrative review and recommendations for public health. Front Psychiatry 2020; 11: 591979.
20. Myran DT, Tanuseputro P, Auger N, et al. Pediatric hospitalizations for unintentional cannabis poisonings and all-cause poisonings associated with edible cannabis product legalization and sales in Canada. JAMA Health Forum 2023; 4(1): e225041.
21. Nešpor K. Marihuana, paměť, soustředění a rozhodování u starších osob. 2023 [online]. Dostupné z: www.drnespor.eu/ THCEld3.doc [cit. 2023-01-31].
22. O‘Grady MA, Iverson MG, Suleiman AO, Rhee TG. Is legalization of recreational cannabis associated with levels of use and cannabis use disorder among youth in the United States? A rapid systematic review. Eur Child Adolesc Psychiatry 2022 May 4. [Epub ahead of print]. PMID: 35508822.
23. Shah R, Ghosh A, Avasthi A, et al. White matter microstructure and gray matter volume in cannabis-induced psychosis and schizophrenia with cannabis use. J Neuropsychiatry Clin Neurosci 2022; 34(4): 406–413.
24. Vaucher J, Keating BJ, Lasserre AM, et al. Cannabis use and risk of schizophrenia: a Mendelian randomization study. Mol Psychiatry 2018; 23(5): 1287–1292.
25. Wilson S, Rhee SH. Causal effects of cannabis legalization on parents, parenting, and children: A systematic review. Prev Med 2022; 156: 106956.
Labels
General practitioner for children and adolescents General practitioner for adultsArticle was published in
General Practitioner
2023 Issue 1
Most read in this issue
- Non-neoplastic portal vein thrombosis
- Pain and neuromodulation – new possibilities
- Health literacy and patient autonomy
- Using health literacy communication strategies in clinical practice